These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
189 related articles for article (PubMed ID: 21148040)
1. Successful colon cancer eradication after chemoimmunotherapy is associated with profound phenotypic change of intratumoral myeloid cells. Medina-Echeverz J; Fioravanti J; Zabala M; Ardaiz N; Prieto J; Berraondo P J Immunol; 2011 Jan; 186(2):807-15. PubMed ID: 21148040 [TBL] [Abstract][Full Text] [Related]
2. Skewing the Th cell phenotype toward Th1 alters the maturation of tumor-infiltrating mononuclear phagocytes. Nonaka K; Saio M; Suwa T; Frey AB; Umemura N; Imai H; Ouyang GF; Osada S; Balazs M; Adany R; Kawaguchi Y; Yoshida K; Takami T J Leukoc Biol; 2008 Sep; 84(3):679-88. PubMed ID: 18566103 [TBL] [Abstract][Full Text] [Related]
3. Cyclophosphamide-induced myeloid-derived suppressor cell population is immunosuppressive but not identical to myeloid-derived suppressor cells induced by growing TC-1 tumors. Mikyšková R; Indrová M; Polláková V; Bieblová J; Símová J; Reiniš M J Immunother; 2012 Jun; 35(5):374-84. PubMed ID: 22576342 [TBL] [Abstract][Full Text] [Related]
4. In vivo elimination of CD25+ regulatory T cells leads to tumor rejection of B16F10 melanoma, when combined with interleukin-12 gene transfer. Nagai H; Horikawa T; Hara I; Fukunaga A; Oniki S; Oka M; Nishigori C; Ichihashi M Exp Dermatol; 2004 Oct; 13(10):613-20. PubMed ID: 15447721 [TBL] [Abstract][Full Text] [Related]
5. Depletion of regulatory T cells facilitates growth of established tumors: a mechanism involving the regulation of myeloid-derived suppressor cells by lipoxin A4. Zhang B; Jia H; Liu J; Yang Z; Jiang T; Tang K; Li D; Huang C; Ma J; Shen GX; Ye D; Huang B J Immunol; 2010 Dec; 185(12):7199-206. PubMed ID: 21068404 [TBL] [Abstract][Full Text] [Related]
6. Intratumoral interleukin-21 increases antitumor immunity, tumor-infiltrating CD8+ T-cell density and activity, and enlarges draining lymph nodes. Søndergaard H; Galsgaard ED; Bartholomaeussen M; Straten PT; Odum N; Skak K J Immunother; 2010 Apr; 33(3):236-49. PubMed ID: 20445344 [TBL] [Abstract][Full Text] [Related]
7. Two distinct mechanisms of augmented antitumor activity by modulation of immunostimulatory/inhibitory signals. Mitsui J; Nishikawa H; Muraoka D; Wang L; Noguchi T; Sato E; Kondo S; Allison JP; Sakaguchi S; Old LJ; Kato T; Shiku H Clin Cancer Res; 2010 May; 16(10):2781-91. PubMed ID: 20460483 [TBL] [Abstract][Full Text] [Related]
8. The requirement of multimodal therapy (vaccine, local tumor radiation, and reduction of suppressor cells) to eliminate established tumors. Kudo-Saito C; Schlom J; Camphausen K; Coleman CN; Hodge JW Clin Cancer Res; 2005 Jun; 11(12):4533-44. PubMed ID: 15958639 [TBL] [Abstract][Full Text] [Related]
9. Synergistic antitumor effects of regulatory T cell blockade combined with pemetrexed in murine malignant mesothelioma. Anraku M; Tagawa T; Wu L; Yun Z; Keshavjee S; Zhang L; Johnston MR; de Perrot M J Immunol; 2010 Jul; 185(2):956-66. PubMed ID: 20548032 [TBL] [Abstract][Full Text] [Related]
10. Successful adoptive immunotherapy of murine poorly immunogenic tumor with specific effector cells generated from gene-modified tumor-primed lymph node cells. Tanaka H; Yoshizawa H; Yamaguchi Y; Ito K; Kagamu H; Suzuki E; Gejyo F; Hamada H; Arakawa M J Immunol; 1999 Mar; 162(6):3574-82. PubMed ID: 10092816 [TBL] [Abstract][Full Text] [Related]
11. The systemic administration of Ig-4-1BB ligand in combination with IL-12 gene transfer eradicates hepatic colon carcinoma. Xu DP; Sauter BV; Huang TG; Meseck M; Woo SL; Chen SH Gene Ther; 2005 Oct; 12(20):1526-33. PubMed ID: 15973445 [TBL] [Abstract][Full Text] [Related]
12. Depleting intratumoral CD4+CD25+ regulatory T cells via FasL protein transfer enhances the therapeutic efficacy of adoptive T cell transfer. Chen A; Liu S; Park D; Kang Y; Zheng G Cancer Res; 2007 Feb; 67(3):1291-8. PubMed ID: 17283166 [TBL] [Abstract][Full Text] [Related]
13. CD4 T cells inhibit in vivo the CD8-mediated immune response against murine colon carcinoma cells transduced with interleukin-12 genes. Martinotti A; Stoppacciaro A; Vagliani M; Melani C; Spreafico F; Wysocka M; Parmiani G; Trinchieri G; Colombo MP Eur J Immunol; 1995 Jan; 25(1):137-46. PubMed ID: 7843224 [TBL] [Abstract][Full Text] [Related]
14. Early exposure of high-dose interleukin-4 to tumor stroma reverses myeloid cell-mediated T-cell suppression. Jiang J; Wang Z; Li Z; Zhang J; Wang C; Xu X; Qin Z Gene Ther; 2010 Aug; 17(8):991-9. PubMed ID: 20410929 [TBL] [Abstract][Full Text] [Related]
15. Tumor regression by anti-CD40 and interleukin-2: role of CD40 in hematopoietic cells and organ-specific effects. Welniak LA; Shorts L; Subleski J; Blazar BR; Wiltrout RH; Murphy WJ Biol Blood Marrow Transplant; 2004 Aug; 10(8):534-9. PubMed ID: 15282531 [TBL] [Abstract][Full Text] [Related]
16. Multiple roles of interferon-gamma in the mediation of interleukin 12-induced tumor regression. Ogawa M; Yu WG; Umehara K; Iwasaki M; Wijesuriya R; Tsujimura T; Kubo T; Fujiwara H; Hamaoka T Cancer Res; 1998 Jun; 58(11):2426-32. PubMed ID: 9622084 [TBL] [Abstract][Full Text] [Related]
17. Intratumoral delivery of IL-12 gene by polyvinyl polymeric vector system to murine renal and colon carcinoma results in potent antitumor immunity. Mendiratta SK; Quezada A; Matar M; Wang J; Hebel HL; Long S; Nordstrom JL; Pericle F Gene Ther; 1999 May; 6(5):833-9. PubMed ID: 10505108 [TBL] [Abstract][Full Text] [Related]
18. In vivo gene transfer of CD40 ligand into colon cancer cells induces local production of cytokines and chemokines, tumor eradication and protective antitumor immunity. Sun Y; Peng D; Lecanda J; Schmitz V; Barajas M; Qian C; Prieto J Gene Ther; 2000 Sep; 7(17):1467-76. PubMed ID: 11001366 [TBL] [Abstract][Full Text] [Related]
19. Cyclophosphamide and IL-12-transduced DCs enhance the antitumor activity of tumor antigen-stimulated DCs and reduce Tregs and MDSCs number. Rossowska J; Pajtasz-Piasecka E; Anger N; Wojas-Turek J; Kicielińska J; Piasecki E; Duś D J Immunother; 2014; 37(9):427-39. PubMed ID: 25304726 [TBL] [Abstract][Full Text] [Related]
20. Distinct responses of two hepatocellular carcinoma cell lines of a similar origin to immunotherapies targeting regulatory or effector T cells. Nagayama Y; Hase W; Motoyoshi Y; Saitoh O; Sogawa R; Nakao K Oncol Rep; 2007 May; 17(5):1269-73. PubMed ID: 17390075 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]